Vyvanse (lisdexamfetamine dimesylate) is a central nervous system (CNS) stimulant used to treat ADHD for patients ages six and above. This animation uses eye-catching visuals and accurate scientific storytelling to explore the mechanism of action of Vyvanse, focussing on drug delivery, administration options, and dosing, as well as important safety information. The animation was produced in two different aspect ratios, making it suitable for widescreen and mobile use.
Vyvance lystexamphetamine dimesylate is a stimulant medication for the treatment of attention deficit hyperactivity disorder or adhd for patients aged six and above vyvanse is indicated for the treatment of attention deficit hyperactivity disorder adhd in patients ages six and above vivants is not indicated or recommended for weight loss use of other sympathomimetic
Drugs for weight loss has been associated with serious cardiovascular adverse events the safety and effectiveness of vivants for the treatment of obesity have not been established cns stimulants amphetamines and methylphenidate containing products including bivance have a high potential for abuse and dependence assess the risk of abuse prior to prescribing and
Monitor for signs of abuse and dependence while on therapy vyvance has the following contraindications known hypersensitivity to amphetamines or other ingredients of vivants anaphylactic reactions stevens-johnson syndrome angioedema and urticaria have occurred use with monoamine oxidase inhibitors maois or within 14 days of stopping maois including maois such as
Lynasalid or intravenous methylene blue because of an increased risk of hypertensive crisis vyvanse or lystex amphetamine dimesylate is an inactive water-soluble pro-drug of dextroamphenomine in which d-amphetamine is bonded to l-lysine a naturally occurring amino acid in general pro-drugs are pharmacologically inert chemical derivatives that are converted in vivo
Into active drug molecules the clinical relevance of the pro-drug formulation of listex amphetamine has not been established the mode of therapeutic action in adhd is not known prior to and during treatment assess for the presence of cardiac disease avoid use in patients with known structural cardiac abnormalities cardiomyopathy serious heart arrhythmia coronary
Artery disease and other serious heart problems sudden death stroke and myocardial infarction have been reported in adults with cns stimulants at recommended doses as well as sudden death in children and adolescents with structural cardiac abnormalities and other serious heart problems while taking cns stimulants at recommended doses further evaluate patients
Who develop exertional chest pain unexplained syncope or arrhythmias while taking byvance cns stimulants cause increases in blood pressure mean increase about two to four millimeters of mercury and heart rate mean increase about three to six beats per minute monitor all patients for tachycardia and hypertension after oral administration list dexamphetamine is
Rapidly absorbed from the gi tract listex amphetamine is converted to dextroamphetamine and l-lysine primarily in blood due to the hydrolytic activity of red blood cells dextroamphetamine is a non-catecholamine sympathomimetic amine with central nervous system stimulant activity amphetamines block the reuptake of the catecholamines norepinephrine and dopamine
Into the presynaptic neuron and increase the release of these monoamines into the extra neuronal space the parent drug listex amphetamine does not bind to the sites responsible for the re-uptake of norepinephrine and dopamine in vitro the clinical significance of in vitro data is unknown the clinical relevance of the pro-drug formulation of lystexamphetamine
Has not been established in summary list dexamphetamine a pro drug of dextroamphetamine is rapidly absorbed from the gastrointestinal tract into the circulatory system where it undergoes a conversion to dextroamphetamine primarily in the blood and then passes to the central nervous system the mode of therapeutic action and adhd is not known exacerbation of
Pre-existing psychosis vivants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder induction of a manic episode in patients with bipolar disorder may induce a mixed manic episode in patients with bipolar disorder prior to initiating treatment screen for risk factors for developing a manic episode
For example comorbid or history of depressive symptoms or a family history of suicide bipolar disorder and depression new psychotic or manic symptoms at recommended doses may cause psychotic or manic symptoms for example hallucinations delusional thinking or mania in patients with no prior history of psychotic illness or mania discontinue if symptoms occur cns
Stimulants have been associated with weight loss and slowing of growth rate in pediatric patients monitor weight and height treatment may need to be interrupted in children not growing or gaining weight as expected cns stimulants including vivants are associated with peripheral vasculopathy including raynaud’s phenomenon signs and symptoms are usually intermittent
And mild very rare sequelae include digital ulceration and or soft tissue breakdown observe patients during treatment for new numbness pain skin color change or sensitivity to temperature in fingers and toes further evaluation may be required including referral increased risk of serotonin syndrome when co-administered with serotonergic agents for example ssris
Snris tryptans and sip2d6 inhibitors but also during overdosage situations discontinue viavance if it occurs and initiate supportive treatment swallowing oral medications can be difficult for some patients only vyvance offers five administration options for patients with adhd to tailor administration to meet the individual needs of appropriate patients chewable
Mixable and swallowable vyvance is available in six chewable tablet strengths chewable vivance tablets must be chewed thoroughly before swallowing take the entire chewable tablet daily do not divide the dose vyvance capsule contents can be mixed with water orange juice or yogurt to administer open capsule and mix contents until completely dispersed stir to break
Apart any compacted powder consume immediately do not store take full contents of capsule do not divide the dose capsules may be swallowed whole and should be taken daily do not divide the dose vyvanse is available in seven capsule strengths with a recommended starting dose of 30 milligrams once daily in the morning avoid afternoon doses due to the potential for
Insomnia the dose may be adjusted in increments of 10 milligrams or 20 milligrams at approximately weekly intervals the maximum dose is 70 milligrams per day capsules and chewable tablets may be taken with or without food and are interchangeable on a unit per unit or milligram per milligram basis for example a 30 milligram capsule for a 30 milligram chewable tablet
In patients with severe renal impairment the maximum dose should not exceed 50 milligrams per day in patients with end-stage renal disease the maximum recommended dose is 30 milligrams per day prior to treatment assess for cardiac disease after prescribing keep prescription records educate patients about abuse monitor for signs of abuse and overdose and re-evaluate
The need for vivant’s use the most common adverse reactions greater than or equal to five percent and at least twice the rate of placebo reported in clinical trials were children aged 6 to 12 decreased appetite insomnia upper abdominal pain irritability vomiting decreased weight nausea dry mouth and dizziness adolescents aged 13 to 17 decreased appetite insomnia
In decreased weight adults decreased appetite insomnia dry mouth diarrhea nausea anxiety and anorexia violence may cause fetal harm breastfeeding is not recommended during vyvanse treatment for more information please visit www.vyvancepro.com
Transcribed from video
Mechanism of Action Animation | ADHD By Random42 Scientific Communication
